Results 161 to 170 of about 72,036 (264)

The Role of IgM Anti‐acetylated Protein Antibodies and B Cells in the Origin of Antimodified Protein Autoimmunity in Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis (RA) is characterized by anti‐modified protein antibodies (AMPAs), including anti‐citrullinated protein antibodies (ACPA), anti‐carbamylated protein antibodies (anti‐CarP), and anti‐acetylated protein antibodies (AAPA). In contrast to other AMPAs, AAPA IgM is found in healthy individuals, raising questions about its role ...
Aegli Athanasiadou   +10 more
wiley   +1 more source

IgG Glycosylation‐Dependent CLEC7A Signaling Drives Podocyte Dysfunction in Lupus Nephritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) that can lead to end‐stage kidney disease and increased mortality. IgG from patients with LN displays abnormal glycosylation, contributing to podocyte injury.
Rohit Upadhyay   +3 more
wiley   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease   +20 more
wiley   +1 more source

Regulatory Research Priorities for AI Use in the Medicine Lifecycle: A European Perspective with Global Relevance. [PDF]

open access: yesClin Pharmacol Ther
Pinheiro LC   +9 more
europepmc   +1 more source

Type I Interferon Drives Dysfunction of a Distinct CD8+ HLA‐DRB1+ T Cell Subset in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is characterized by type I interferon (IFN) signaling and adaptive immune dysregulation. We previously identified hypomethylation of HLA‐DRB1 and STAT1 in SLE CD8+ T cells, enabling aberrant IFN‐driven HLA‐DRB1 expression and expansion of a distinct CD8+ T cell subset. This study characterized CD8+ HLA‐DRB1+
Huizhong Long   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy